BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol 2021:S0190-9622(21)01119-1. [PMID: 34126094 DOI: 10.1016/j.jaad.2021.06.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Pendlebury GA, Oro P, Ludlow K, Merideth D, Haynes W, Shrivastava V. Relevant Dermatoses Among U.S. Military Service Members: An Operational Review of Management Strategies and Telemedicine Utilization. Cureus 2023. [DOI: 10.7759/cureus.33274] [Reference Citation Analysis]
2 Wu PC, Dai YX, Li CL, Chen CC, Chang YT, Ma SH. Dupilumab in the treatment of genodermatosis: A systematic review. J Dtsch Dermatol Ges 2023;21:7-17. [PMID: 36657040 DOI: 10.1111/ddg.14924] [Reference Citation Analysis]
3 Wu PC, Dai YX, Li CL, Chen CC, Chang YT, Ma SH. Dupilumab zur Behandlung von Genodermatosen: Eine systematische Übersicht. J Dtsch Dermatol Ges 2023;21:7-18. [PMID: 36721935 DOI: 10.1111/ddg.14924_g] [Reference Citation Analysis]
4 Chromy D, Bartosik T, Brkic FF, Quint T, Tu A, Eckl-Dorna J, Schneider S, Bangert C. Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis. J Dermatol 2023;50:89-93. [PMID: 36177732 DOI: 10.1111/1346-8138.16595] [Reference Citation Analysis]
5 Thurston AW, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. Am J Clin Dermatol 2022. [DOI: 10.1007/s40257-022-00741-9] [Reference Citation Analysis]
6 Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. Journal of Allergy and Clinical Immunology 2022. [DOI: 10.1016/j.jaci.2022.10.023] [Reference Citation Analysis]
7 Yang CY, Lai PJ, Chen CB, Chan TC, Hui RC, Huang YH, Tseng HC, Lin SH, Lu CW, Lee HE, Lin JY, Chi MH, Tsai MF, Hwang YS, Wang CW, Chu CY, Chung WH. Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study. J Clin Med 2022;11:6209. [PMID: 36294530 DOI: 10.3390/jcm11206209] [Reference Citation Analysis]
8 Pappa G, Sgouros D, Theodoropoulos K, Kanelleas A, Bozi E, Gregoriou S, Krasagakis K, Katoulis AC. The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis. JCM 2022;11:5633. [DOI: 10.3390/jcm11195633] [Reference Citation Analysis]
9 Li W, Man XY. Immunotherapy in atopic dermatitis. Immunotherapy 2022. [PMID: 36046941 DOI: 10.2217/imt-2022-0054] [Reference Citation Analysis]
10 Miyagawa F. Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases. Biomedicines 2022;10:1485. [DOI: 10.3390/biomedicines10071485] [Reference Citation Analysis]
11 Goh MS, Yun JS, Su JC. Management of atopic dermatitis: a narrative review. Med J Aust 2022;216:587-93. [PMID: 35644531 DOI: 10.5694/mja2.51560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moshirfar M, Seitz T, Ply B, Ronquillo YC, Hoopes PC. Corneal Refractive Surgery Considerations in Patients on Dupilumab. J Clin Med 2022;11:3273. [PMID: 35743344 DOI: 10.3390/jcm11123273] [Reference Citation Analysis]
13 Bakulev AL, Vishneva EA, Elisyutina OG, Ilyina NI, Karamova AE, Kokhan MM, Kubanov AA, Monakhov KN, Namazova-baranova LS, Novik GA, Olisova OY, Revyakina VA, Sokolovskiy EV, Fedenko ES, Khobeysh MM. Resolution of the Working Meeting of Experts in “Dermatology”: Possibilities of systemic therapy of atopic dermatitis with selective immunosuppressants. Russian Journal of Allergy 2022;19:259-269. [DOI: 10.36691/rja1546] [Reference Citation Analysis]
14 Simpson E, Simpson E. JAK inhibitors in AD: Setting the efficacy bar even higher. Medicom Conference Report AAD 2022 2022. [DOI: 10.55788/32a5e773] [Reference Citation Analysis]
15 Simpson E, Simpson E. JAK inhibitors in AD: Setting the efficacy bar even higher. Medicom Conference Report AAD 2022 2022. [DOI: 10.55788/b82b0ac2] [Reference Citation Analysis]
16 Muzumdar S, Skudalski L, Sharp K, Waldman RA. Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. Am J Clin Dermatol 2022;23:61-7. [PMID: 34855151 DOI: 10.1007/s40257-021-00646-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dodson J, Lio PA. Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases. Curr Allergy Asthma Rep 2022;22:183-93. [PMID: 36348149 DOI: 10.1007/s11882-022-01047-w] [Reference Citation Analysis]
18 Narla S, Silverberg JI. Dermatology for the internist: optimal diagnosis and management of atopic dermatitis. Ann Med 2021;53:2165-77. [PMID: 34787024 DOI: 10.1080/07853890.2021.2004322] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]